Early adjustments are usually easier than trying to reverse larger regain later
2023 NEJM Phase 2 obesity trial used a starting dose of 2 mg once weekly with dose escalation every 4 weeks, reaching a maximum tested maintenance dose of 12 mg/week [1][2]
The most familiar challenges reported were: A general change in flavour perception Increased sensitivity to sweetness Increased sensitivity to bitterness These responses were observed across several GLP-1 medications, including Ozempic, Wegovy and Mounjaro, suggesting the experience may be linked to the treatment mechanism rather than a specific brand
B85502, Invitrogen) cultured in flat culture flasks were grown until confluent in Express Five SFM Medium (Gibco) supplemented with 200 mM l-glutamine (Sigma-Aldrich) and 1 Antibiotic-Antimycotic solution (Sigma-Aldrich) at 27 C
The difference in how I feel day to day is hard to describe
The volume of BAC water used determines the final concentration of the reconstituted solution
